This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Lilly bought the plant in Pleasant Prairie ... drive that aims to shore up supplies of drugs like diabetes therapy Mounjaro and Zepbound for obesity, both based on GIP/GLP-1 dual agonist tirzepatide.

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue increase Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.

In the fourth quarter, top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...